Management of a Patient With Advanced BRAF-Mutant Melanoma

Given the recent expansion of treatment options in advanced melanoma, oncologists now have the opportunity to choose among multiple effective and fairly well-tolerated treatment options. The appropriate sequence and combination of targeted agents and immunotherapy are currently under investigation. Guidelines are evolving rapidly in both the adjuvant and metastatic settings with the accumulation of clinical experience and new trial outcomes. A 49-year-old man initially diagnosed in 1995 with cutaneous melanoma presented to the authors’ care in 2009 with metastatic, BRAF V600E–mutant melanoma. His treatment course to date has included surgery, adjuvant radiotherapy, and interferon, metastasectomies, granulocyte-macrophage colony-stimulating factors, a clinical trial with the BRAF inhibitor (BRAFi) vemurafenib (PLX-4032), clinical trial with combination BRAF plus MEK inhibition with vemurafenib plus GDC-0973, and combination targeted and immune therapy with vemurafenib plus the anti-CTLA4 antibody ipilimumab. This case report illustrates the long-term management of a patient with metastatic melanoma using targeted and immune therapy, evolution in treatment guidelines, next directions in research, and the critical role of clinical trials in advancement of patient care.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the long-term management of patients with metastatic melanoma using targeted therapy and immunotherapy
  • Summarize the evolution in treatment guidelines ofpatients with metastatic melanoma
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
03/10/2014
Course expires: 
03/10/2015
Cost:
$0.00

Michelle T. Ashworth, MD
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco San Francisco, California

Adil Daud, MD
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco San Francisco, California

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Accreditation Period

Course opens: 
03/10/2014
Course expires: 
03/10/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing